safescimet

European Modular Education and Training Programme in Safety Science for Medicines

Universität Konstanz

efpia

safescimet course 1.2 - Safety and Efficacy of Cell Therapies

(30 March–02 April 2020, Konstanz, Germany)

A unique opportunity to broaden your knowledge of drug discovery and development with special emphasis on drug safety.

safescimet offers an outstanding faculty of academic and industry experts and an interactive programme, including case studies from the pharmaceutical industry provding a broad understanding of the latest developments in safety sciences.

This course introduces the emerging area of the applications of cell therapies in the treatment of diseases, including mesenchymal stromal cells and stem cells. It addresses the key issues of safety and efficacy that need to be considered by developers of these therapies, including academics and the pharmaceutical/biotech industry, as well as the important area of regulation. The use of cell therapies in a range of disease models and clinical trials will be discussed. The course will also provide insight into the use of stem cells in the screening of conventional drugs for efficacy and particularly safety. European leaders in these fields, from Industry, Academia and the Regulatory Agencies, will contribute teaching sessions in a small, informal and interactive learning environment.

Key Subjects

- Basic biology of cells used as cell therapies, including mesenchymal stromal cells of various origins, and stem cells
- Key issues: efficacy and safety of using cell therapies
- Considerations for preclinical and clinical applications of mesenchymal stromal cells/stem cells
- Insight into progress in preclinical and clinical studies using cell therapies
- Introduction to immune system and importance in regenerative medicine therapies
- Use of stem cells in safety assessment - where we are
- New nanoparticles and reporters for imaging and tracking cell therapies
- Regulatory requirements for cell therapies and stem cells and as well as extracellular vesicles

Learning Outcomes

- Gain an understanding of where the science has reached
- Appreciate the novelty of these areas and the concomitant challenges to therapy developers and the regulators
- Understand that there are still many gaps in our knowledge – i.e. concept of an evolving area
- Understand th basic biology that underpins this field and that is being translated into man
- Appreciate the utility and possible drawbacks of different preclinical models for assessment of safety
- Overview the state of the art in the application of stem cells in safety assessment of conventional compounds

Link to apply to this course

Deadline for registration 24 March 2020



Bioluminescence imaging of mice after administration of human mesenchymal stromal cells into the tail vein (left) or left ventricle (right)

Course Organisers

Prof Dr Daniel Dietrich
Human and Environmental Toxicology, Faculty of Biology, University of Konstanz, Germany

Prof Christopher Goldring
MRC Centre for Drug Safety Science, University of Liverpool, UK

Dr Bettina Wilm
Department of Cellular and Molecular Physiology, University of Liverpool, UK

Participant Feedback

Course provided practical case lectures that helped me better understanding the theory.

Quality and closeness of teachers were great! They were available for questions and discussion of any course topic.

safescimet Executive Office
University of Konstanz, Universitätsstraße 10, Box 622, 78457 Konstanz, Germany; Phone +49 7531 88 3518/3171
To contact us or to register to our courses visit safescimet@uni-konstanz.de or http://ssm.afww.uni-konstanz.de/safescimetcourses

safescimet is currently supported by Hoffmann-La Roche & Sanofi & Bayer Healthcare AG & Deptartment Human and Environmental Toxicology at the University of Konstanz